Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева (Jul 2018)

A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine

  • Alberto Muratorio,
  • Ubaldo Bonuccelli,
  • Angelo Nuti,
  • Noe Bavpistini,
  • Stefano Passero,
  • Vittoria Caruso,
  • Barbara Batani,
  • Alberto Baroni,
  • Federico Mayer,
  • Tiziana Sorbi,
  • Attilio Franciosi,
  • Gianni Moro,
  • Luciano Agostini,
  • Massimo Piccirilli,
  • Diana Scatozza

Journal volume & issue
Vol. 0, no. 2
pp. 53 – 60

Abstract

Read online

A multicenter, unblinded, randomized, controlled clinical trial was conducted to evaluate the efficacy and tolerability of L-aglycerylphosphorylcholine (L-a-GPC) 1 gm/day IM compared with that of cytidine diphosphocholine (CDP-choline) 1 gm/day IM in 112 patients with mild to moderate multi-infarct dementia. A 90-day treatment period with the test drug was followed by a 90-day follow-up period without treatment to observe how long the results obtained with treatment could be maintained. A total of 97 patients completed the treatment period; of these, 73 completed the follow-up period. Eighteen patients did not complete the study because of poor compliance, and 21 patients at one center were not followed up. Treatments were started after a 2-week washout period during which other drugs that could affect cognitive function were withdrawn. Clinical efficacy was evaluated by comparing the results at baseline, after 30 days, at the end of treatment, and at the end of the follow-up period on the following psychometric tests: the Sandoz Clinical Assessment Geriatric (SCAG) Rating Scale, the Blessed Dementia Scale, the Blessed Information, Memory, Concentration test, the Wechsler Memory Scale (WMS), the Rapid Disability Rating Scale 2 (RDRS 2), the Word Fluency test, the Token test, and the Simple Drawing Copy (SDC). The patients receiving L-a-GPC showed a significant improvement of cognitive functions, behaviour, and personality at the end of the treatment, compared with baseline values. This improvement was still apparent at the end of the follow-up period. A comparison of the results obtained with L-a-GPC and CDP-choline shows that the performance of the patients treated with L-a-GPC was significantly better than that of the CDP-choline group on the Blessed Dementia Scale, WMS, RDRS 2, and SDC at the end of treatment and on the Blessed Dementia Scale, WMS, SCAG, and Token test at the end of the follow-up period.

Keywords